VJ Oncology· @VJOncology · X·· 15 小时前评分45
正文 · 机器翻译
在 #ESMO26，Hina Khan (@BrownMedicine) 讨论了一项关于广泛期 SCLC 中使用 #tarlatamab 所致细胞因子释放综合征的真实世界分析，以及其与试验数据的比较
@myESMO #LCSM #SCLC
77 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
3821P按 SCLC 对上
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.org3848P按 SCLC 对上
Cytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgLBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：VJ Oncology · x.com